Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation

被引：14
|
作者：
Restelli, Valentina [1 ]
Vagni, Micaela [1 ]
Arribas, Alberto J. [2 ]
Bertoni, Francesco [2 ,3 ]
Damia, Giovanna [1 ]
Carrassa, Laura [1 ]
机构：
[1] IRCCS, Ist Ric Farmacol Mario Negri, Dept Oncol, Lab Mol Pharmacol, Milan, Italy
[2] IOR Inst Oncol Res, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[3] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 01期
关键词：
diffuse large B cell lymphoma; CHK1; WEE1; MYC; combined targeted therapy; PHASE; COMBINATION; CANCER;
D O I：
10.1111/bjh.14506
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：129 / 133
页数：5
相关论文
共 50 条
  • [41] ING2 loss sensitizes KRAS-mutated NSCLC to WEE1 inhibition through regulation of CHK1 expression.
    Ricordel, Charles
    Thalappilly, Subash
    Archambeau, Jerome
    Chan, Angela
    Nixon, Nancy
    Desrues, Benoit
    Bebb, Gwyn
    Riabowol, Karl
    Pedeux, Remy
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 57 - 57
  • [42] In silico and structure-based evaluation of deleterious mutations identified in human Chk1, Chk2, and Wee1 protein kinase
    Colaco, Venessa
    Goswami, Nabajyoti
    Goel, Vijay Kumar
    Srivastava, Sunil Kumar
    Lalrohlua, Pachuau
    Senthil Kumar, Nachimuthu
    Borah, Probodh
    Baruah, Reshita
    Varma, Ashok K.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2024, 125 (01) : 89 - 99
  • [43] PARG and WEE1 inhibition in GI cancers: A novel synergistic, targeted therapeutic approach
    Agostini, Lebaron C.
    Jain, Aditi
    Pishvaian, Michael
    Yeo, Charles
    Brody, Jonathan
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition
    Wang, Xiaoguang
    Chen, Zhangguo
    Mishra, Ameet K.
    Silva, Alexa
    Ren, Wenhua
    Pan, Zenggang
    Wang, Jing H.
    HAEMATOLOGICA, 2018, 103 (03) : 466 - 476
  • [45] CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.
    Morales-Espinosa, Daniela
    Garcia-Roman, Silvia
    Molina-Vila, Miguel Angel
    Capitan, Ana Gimenez
    Bertran-Alamillo, Jordi
    Mendez, Pedro
    Ramirez, Santiago Viteri
    Karachaliou, Niki
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family
    Pouliot, Lynn M.
    Chen, Yu-Chi
    Bai, Jennifer
    Guha, Rajarshi
    Martin, Scott E.
    Gottesman, Michael M.
    Hall, Matthew D.
    CANCER RESEARCH, 2012, 72 (22) : 5945 - 5955
  • [47] G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1
    Busch, C. J.
    Kroeger, M. S.
    Jensen, J.
    Kriegs, M.
    Gatzemeier, F.
    Petersen, C.
    Knecht, R.
    Rothkamm, K.
    Rieckmann, T.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S61 - S62
  • [48] Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies
    Vakili-Samiani, Sajjad
    Jalil, Abduladheem Turki
    Abdelbasset, Walid Kamal
    Yumashev, Alexei Valerievich
    Karpisheh, Vahid
    Jalali, Pooya
    Adibfar, Sara
    Ahmadi, Majid
    Feizi, Abbas Ali Hosseinpour
    Jadidi-Niaragh, Farhad
    DNA REPAIR, 2021, 107
  • [49] MYC Alterations in Diffuse Large B-Cell Lymphomas
    Karube, Kennosuke
    Campo, Elias
    SEMINARS IN HEMATOLOGY, 2015, 52 (02) : 97 - 106
  • [50] Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis
    Wang, YL
    Decker, SJ
    Sebolt-Leopold, J
    CANCER BIOLOGY & THERAPY, 2004, 3 (03) : 305 - 313
12345